



RESEARCH STUDIES

1. What is the name of the study? **A Study of RO5313534 as Add-on therapy to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease**
2. When does the recruitment start and finish? **Recruitment started in May 2009 and will run for several months.**
3. How is the study being funded? **The pharmaceutical company that owns and develops RO5313534.**
4. What is being investigated? **An new investigational drug (a pill), known as RO5313534.**
5. Why is the study important? **While other drugs available for Alzheimer's disease improve symptoms in some patients, the response is not satisfactory for the majority of patients treated. The drug RO5313534 is being developed to see if it can potentially improve memory, attention, and thinking in patients with mild to moderate Alzheimer's disease.**
6. Who can participate? **Male and female patients aged 50 and older who have been diagnosed with mild to moderate Alzheimer's disease and who are taking donepezil alone (Aricept®) as treatment.**
7. Who cannot participate? **Patients with Alzheimer's disease who are taking other drugs to treat their disease (Ebixa®, Reminyl®, Exelon®).**
8. What is required of the participants? **Participants will need to come to clinic with their caregiver 11 times in 6 months, and have a variety of memory and thinking tests. They will also have regular blood tests and heart monitoring.**
9. What are the potential benefits and limitations of participating?
 - **It is possible the participant may have an improvement in their symptoms of Alzheimer's disease, but this cannot be guaranteed. The results of this study may help other patients in the future by giving important information about RO5313534 and the potential treatment of Alzheimer's disease.**



- **About 25% of patients in this study will receive a placebo (dummy drug). Placebo treatment is very important to ensure the study is done in a scientific way.**
- **Like all medications, it is possible the study drug may cause some side effects.**

10. Has the study been approved by an ethics committee? (please provide details)

The study has been reviewed by Health Canada and reviewed by IRB Services Ethics Review Board.

11. How large is the study? **About 360 pts will take part in this study world-wide.**

12. Where are the study sites? **The study is being conducted at 10 different centres across Canada. In Toronto, it is being conducted at the Toronto Memory Program.**

13. Where can one obtain more information?

**Please contact: Toronto Memory Program
Laura Wilson
Tel: (416) 386-9761 ext 309
lwilson@memorydisorders.ca**

14. Any additional comments? **Patients will be re-imbursed for travel expenses incurred to attend the clinic visits.**

The contents of this document are provided for information purposes only by the Alzheimer Society of Toronto and do not represent an endorsement or a recommendation with respect to the research study and/or the claims and properties thereof.